Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Evoke Pharma (NASDAQ:EVOK) reported its Q4 earnings results on Thursday, March 14, 2024 at 04:10 PM.
Here's what investors need to know about the announcement.
Evoke Pharma missed estimated earnings by -18.0%, reporting an EPS of $-0.59 versus an estimate of $-0.5.
Revenue was up $880 thousand from the same period last year.
Last quarter the company beat on EPS by $0.11 which was followed by a 2.0% drop in the share price the next day.
Here's a look at Evoke Pharma's past performance:
Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
---|---|---|---|---|
EPS Estimate | -0.62 | -0.73 | -0.58 | -0.53 |
EPS Actual | -0.51 | -0.56 | -0.67 | -0.54 |
Revenue Estimate | 1.26M | 1.10M | 1.00M | 890K |
Revenue Actual | 1.56M | 1.13M | 810K | 796K |
To track all earnings releases for Evoke Pharma visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: EVOK